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Abstract
Background: Maternal dengue antibodies are considered to play a significant role in dengue pathogenesis among
infants. Determining the transplacental specific antibody transfer is invaluable for establishing the optimal
vaccination age among infants in endemic regions.
Methods: We conducted a cross-sectional study among pairs of maternal and corresponding umbilical cord blood
samples in public hospitals. The prevalence and incidence of dengue infection were determined in 505 pairs of
pregnant women and neonates during a large outbreak (2009–2010) in central Brazil. The women were interviewed
at late pregnancy to assess current or past symptoms of dengue. All parturients and their neonates were screened
using Dengue IgG Indirect ELISA (Panbio) to assess previous dengue exposure. A semi-quantitative measurement of
the IgG antibody expressed by the index ratio was calculated using optical density (OD) values according to the
manufacturer’s instructions. The studied population of parturients and their offspring was also screened for recent
dengue infection by the Dengue IgM-capture ELISA (Panbio). Those participants with history of fever and two or
more symptoms of dengue at least 10 days before the delivery were also tested for the dengue NS1 antigen using
the Dengue Early ELISA (Panbio) and RT-PCR.
Results: The mean maternal age was 25.8 (SD = 6.4), and 83.6% of deliveries were between 37 and 41 weeks.
Approximately half of the 505 women and neonates were IgG-seropositive, yielding 99.3% co-positive mother-child
frequency of antibody transfer (Kappa = 0.96). The incidence of dengue infection was 2.8% (95% CI 1.4–4.4%)
among the women considering 14 IgM-positive results and one DENV2 detected by RT-PCR. The dengue NS1
antigen was undetectable in the matched pairs.
Conclusion: This study provides critical data on the prevalence of transplacental transferred maternal-infant anti-
dengue antibodies and incidence of infection. The design of future vaccine trials should consider diverse regional
epidemiological scenarios.
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Background
Dengue is a vector-borne disease caused by four distinct
serotypes (DENV1, 2, 3 and 4), and approximately 3
billion people live or travel in regions infested by Ae.
aegypti mosquitoes, which are considered the main
vector [1]. Dengue has been one of the most important
public health issues in tropical and subtropical regions
of the world due to the spread of the vector infestation
in domestic environments and the potential of DENV
infection to cause successive epidemics in highly urban-
ized settings [2]. DENV infection may progress from
asymptomatic to a spectrum of clinical diseases, from
mild dengue cases to fatal dengue haemorrhagic fever or
dengue shock syndrome (DHF/DSS) [1,3]. Infected indi-
viduals may mount a protective immune response for
each specific serotype but only short-term heterologous
protection against the other serotypes [4]. Consequently,
naive populations have a four-fold risk of becoming
infected and developing a clinical disease in response to
each circulating serotype. Vector control programs have
been considered costly, and achieving a sustainable
reduction in infestation to low levels is difficult, both of
which appear necessary to interrupt the chain of trans-
mission in endemic regions [5]. Potential safe vaccines
are under Phase III preventive trials and still need to be
tested at a large scale in different endemic settings.
Since the reintroduction of DENV1 in Brazil the late
80’s, the spread of DENV has been reported throughout
the country, particularly in the south-eastern and north-
eastern regions [6,7]. The isolation of DENV2 was
reported in 1990, followed by DENV3 (2000) and
DENV4, which were re-introduced in the last two years
in most regions [6,8]. More than 1.2 million dengue
cases were registered from 2010 to September 2011, in
contrast to the 200 thousand registered during 1996–
2002. In addition, the proportion of severe clinical forms
increased from 0.06% in the 90’s to 0.38% in 2002–2008.
These official national data showed growth not only in
the incidence but also in the severity of dengue.
Although adults are still the most affected population, a
steady rise in DENV incidence and hospitalization
among children reflects a shift toward a younger age
distribution and severity over the past ten years [9]. In
part, these current Brazilian epidemiological trends
resemble the characteristics of the age distribution of
dengue in Southeast Asia, where dengue is a childhood
illness. These trends are also in agreement with the
theory of dynamic viral infection because the children
become the susceptible population after the adults have
been infected and immune [10].
Pregnant women and infants are considered a vulner-
able group for developing the severe dengue clinical
forms according to international and national guidelines.
There is no consensus in the literature about the adverse
effects of dengue on pregnancy and/or neonates [11,12].
In general, maternal dengue antibodies may play a dual
role in the pathogenesis of the dengue disease in the ne-
onates. In the early months of life, transplacental dengue
antibodies may protect the infant but may also enhance
the risk of developing DHF/DSS due to suboptimal
neutralizing antibodies [13,14]. Several studies have sug-
gested that the development of DHF may be related to
secondary infections by heterologous serotypes among
children and adults or that DHF can occur during the
first infection of children who received maternal IgG
antibodies [15]. This hypothesis is reinforced by the
evidence from Southeast Asia that severe dengue disease
in early childhood is mainly due to primary dengue
infection [16,17].
This manuscript aims to determine the prevalence of
past and recent dengue infections among parturients and
their offspring during late pregnancy in central Brazil.
Methods
Study setting
We conducted a cross-sectional study among pairs of
maternal and corresponding umbilical cord blood
samples in two public hospitals located in the city of
Goiânia-GO (1.3 million inhabitants) [18] in central
Brazil from December 2009 to May 2010. In this set-
ting, the surveillance system registered the first dengue
cases in 1994 and detected the co-circulation of three
serotypes (DENV1, DENV2 and DENV3) since the year
2002 [19]. During the study period, DENV1 was the
predominant virus isolated, replacing the previous pre-
dominance of DENV3 circulation between 2002 and
2008 [20]. DENV4 was only detected after the study
period (year 2011). In this region, the attack rates were
2.050/100.000 inhabitants (N = 24.603 reported cases)
and 3.619/100.000 inhabitants (N = 43.436 cases) for
the years 2009 and 2010, respectively [21]. The field
work was conducted during a dengue epidemic that
occurred in the study setting and in other Brazilian
states in 2010 [20].
In this study, 505 parturients were recruited, mean
maternal age was 25.8 years (SD = 6.4), and 83.6% of the
deliveries were between 37 and 41 weeks. The majority
of the participants were unemployed; 60.3% and 24.3%
self-referred as biracial or white, respectively. The inclu-
sion criteria were all parturients who were hospitalized
during labour and delivery and were residents of the
study area, independent of the gestational risk and/or
history of infectious or chronic diseases. We also included
their neonates.
The parturients were interviewed to collect data on
the residence, socio-demographic features, previous
dengue episodes and yellow fever vaccination. The main
characteristics of the gestational period and delivery
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were extracted from the medical records. For the neo-
nates, the data were extracted from the official system of
live birth registrations (Ministry of Health, Declaration
of live births), including the Apgar, birth weight, type of
delivery and sex of the neonates. For the women, blood
specimens (5 mL) were collected during hospitalization
within 48 hrs after delivery. For the neonates, the umbil-
ical cord blood was collected as a routine procedure at the
time of delivery. The serum samples were stored until ana-
lysis in aliquots at −20°C for serological tests and at −70°C
for RT-PCR.
Laboratory tests
All parturients and their neonates were screened using
Dengue IgG Indirect ELISA kits (Inverness Medical Inno-
vations Australia Pty Ltd, Queensland, Australia) to assess
the previous dengue exposure. A semi-quantitative meas-
urement of the IgG antibody expressed by the index ratio
was calculated using optical density (OD) values according
to the manufacturer’s instructions. The studied population
of parturients and their offspring were also screened for
recent dengue infection by the Dengue IgM-capture
ELISA (Inverness Medical Innovations Australia Pty Ltd).
Seropositive IgM samples were retested using an in-house
IgM capture ELISA test and were considered positive if
the ratio of the optical density of the positive to negative
controls was at least two [22,23].
Those participants with history of fever and two or
more symptoms of dengue at least 10 days before the
delivery were also tested for the dengue NS1 antigen
using the Dengue Early ELISA (Panbio diagnostics,
Australia) and RT-PCR. Viral RNA was extracted from
serum samples using a purification column from the
PureLink™ Viral RNA/DNA Kit (Invitrogen, Carlsbad,
CA), and conventional one-step and nested PCR [24]
was performed to identify the serotype. If the women
were identified as recently infected, their neonates were
also tested with the dengue NS1 antigen and RT-PCR
tests to assess the vertical DENV transmission.
Past and recent infection definitions
IgG-positive results were considered to indicate previous
dengue exposure among parturients or IgG placental
transfer in the umbilical cord serum samples. Simultan-
eously positive results by IgM PanBio and MacElisa and
the detection of the dengue NS1 antigen and/or positive
RT-PCR results were considered to indicate a recent
DENV infection.
Sample size
A sample of 500 parturients was sufficient to estimate
the frequency of ~50% of the dengue infection with 4.5%
precision at a 95% confidence interval (95% CI).
Data analysis
The descriptive data analyses were performed to evaluate
the main characteristics of the women and neonates.
The prevalence of previous and recent dengue infection
and its 95% CI were estimated.
The agreement between the IgG positivity of the
matched pairs of parturients and their neonates was calcu-
lated using the Kappa test. The correlation between the
maternal and corresponding umbilical cord serum IgG
antibodies indices was calculated (R2) and presented in a
scatter plot.
The positive and negative predictive values (PPV and
NPV) of the self-reporting of past dengue episodes com-
pared with the serologic results were calculated.
All analyses were performed using SPSS 17.0 (SPSS
Inc., Chicago, IL) and EpiInfo (CDC 3.5.1 version).
Ethical issues
This project was approved by the regional Medical Ethics
Committee of Humans and Animals of the University
Hospital, Federal University of Goias (no 078/2009). All
women signed the informed consent regarding their
own participation and for the umbilical cord blood
specimens and data collection of their offspring. For
underage women, the informed consent was signed by
their legal guardians.
Results
Among the 505 parturients recruited, the prevalence of
previous dengue infection was 53.9% (95% CI: 49.4–
58.3%). Among new-borns, a 55.0% (95% CI: 50.6–
59.4%) IgG seropositivity was detected, yielding 99.3%
co-positivity for placental antibody transfer (Kappa =
0.96). There was no statistic difference between the posi-
tivity of pregnant women and neonates, considering the
overlap of the confidence intervals (Table 1). Figure 1
shows the linear correlation between the maternal and
neonatal anti-dengue IgG index values (R2=0.93).
A previous history of dengue was reported by 100
pregnant women, yielding 88% (95% CI: 79.6–93.4%) for
the positive predictive value (PPV). Of the 405 women
with no reported dengue history, 184 were IgG seroposi-
tive (45.4%; 95% CI: 40.9–50.2%). A history of yellow
fever vaccination was reported by 82.0% of women who
had IgG anti-dengue antibodies and by 86.8% without
this seromarker of infection.
Overall, 9.3% women reported dengue symptoms or
dengue disease during pregnancy, and 1.4% (n = 7) had
symptoms in the 10 day period preceding the delivery.
For one parturient with recent symptoms at the delivery
time DENV2 was detected by RT-PCR but NS1 antigen
or IgM antibody were undetectable.
Of the 505 screened parturients, 44 were IgM positive
by Panbio, 14 were simultaneously positive by both the
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commercial and in-house IgM capture-ELISA, and 4
were indeterminate. The frequency of recent infection
was 2.8% (95% CI: 1.4–4.4%).
Of the 505 serum cord samples, 4.7% (95% CI: 3.0–
6.9%) had IgM anti-dengue antibodies (n = 24) by the
commercial kit (Panbio), but no IgM positivity was
detected by the in-house ELISA test.
Discussion
In central Brazil with nearly 15 years of continuous den-
gue virus circulation, approximately half of the pregnant
women screened had detectable dengue antibodies.
Our study showed a high agreement of IgG seropositiv-
ity between the pairs of pregnant women and their neo-
nates (99.3%), in agreement with studies from Southeast
Asia [25-27]. In our study, there was a positive correlation
of the maternal-foetal specific IgG anti-dengue antibody,
and even higher levels of the antibody were observed in
some offspring samples compared with their mothers.
This finding reflects the dynamics of IgG placental trans-
fer, which increases according to the length of gestation
and peaks during the last weeks of pregnancy, a well-
documented immune process described for several infec-
tious diseases [28].
Reports of clinical dengue symptoms during the gesta-
tional period was not common, with most of the parturi-
ents being asymptomatic in the short period preceding
delivery, even considering that the field study was
conducted during the 2010 outbreak. A high ratio of
asymptomatic versus symptomatic dengue infection is in
agreement with other studies conducted among preg-
nant women [29] and in the general population [30-32].
Because asymptomatic dengue infections are a common
finding, studies aiming to detect the prevalence and inci-
dence of dengue infections among pregnant women and
infants are valuable to evaluating the maternal antibody
transfer and the dynamics of dengue transmission [10].
Our finding that approximately half of the adult popu-
lation that was screened was still immunologically naïve
to dengue virus exposure appears compatible with the
more recent viral re-introduction in central Brazil [31].
There was a lag period of approximately 10 years
between the first dengue virus isolation in the Atlantic
coast (1985) and its spread toward central part of the
country (1994), where this investigation was performed
[31]. In a city located in the north-eastern costal region,
a population-based serosurvey presented an approxi-
mately 90% infection rate among adults in the early
2000’s [30]. Considering that Brazil is a continental
country, a large variation in the prevalence of dengue
infection has been detected by the serosurveys, based on
the study setting and the cumulative period of virus ex-
posure at the population level. Nevertheless, the dengue
seroprevalence detected in central Brazil contrasts with
the more established dengue circulation of more than
five decades in Southeast Asia, in which the adults have
mounted immunological responses for all dengue sero-
types but the children are the main susceptible group for
acquiring dengue infection [27,33].
The incidence of recent infection varied from 2.8%
when using commercial test to 8.7% using in-house-test,
pointing out differences in sensitivity and specificity of
these assays. Approximately 2.0% of IgM seropositivity
was detected among parturients in our setting when both
anti-dengue virus immunoglobulin M tests (commercial
and in-house) were simultaneously positive, according to
Table 1 Frequency of past and recent dengue infection among parturients and the umbilical cord sera and the Kappa
agreement for IgG placental transfer
Dengue infection Parturients Cord serum Kappa
(n = 505) (n = 505)
Past Infection
IgG positive (95% CI) 53.9% (49.4–58.3) 55.0% (50.6–59.4)* 0.96
Recent infection
IgM**positive and RT-PCR detection (95% CI) 2.8% (1.4–4.4) 0% na
* IgG placental transfer.
**IgM positivity: commercial and in house ELISA tests.
na; not applicable.
Figure 1 Correlation between maternal and umbilical cord
serum of anti-dengue IgG antibodies.
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the recent infection definition of this research protocol.
The evaluation of the commercially available anti-dengue
virus IgM tests indicates that although the Panbio IgM
capture presents a sensitivity and specificity of approxi-
mately 80%, varying with the different serotypes and be-
ing less accurate among individuals exposed to previous
dengue infection [34-36]. Furthermore, the in-house
test applied here was formulated/constituted by the
Brazilian DENV antigens in circulation, which may con-
fer a higher specificity. As most of the parturients were
asymptomatic and the DENV viraemia period is short
(~five days), the investigation of recent infection by
virological markers was not feasible in this type of
cross-sectional design.
Similar results of recent infection around 2% were
found among parturients in Southeast Asia during 2006
[29]. The frequency of IgM positivity in both maternal and
umbilical cord blood was approximately 8% by commer-
cial ELISA compared with 2.0% in parturients by the in-
house test. In the umbilical cord blood, no anti-dengue
IgM was detected by the in-house test. The absence of
IgM antibodies in the cord serum is in line with the
general knowledge that this pentamer immunoglobulin
only crosses the placental barrier in rare situations [37].
The apparent discrepancy of the recent infection re-
sults, according to the different laboratorial methods
employed may be explained by the dynamic of virus ex-
posure and the time sequence of the immune response
[38]. For example, IgM antibodies may be detected after
the 7 days of onset of symptoms to two to three months
after viral exposure in contrast with the short time
circulation (days) of the dengue viremia. Therefore, the
detection of IgM antibodies in samples collected closely
to labor indicate recent dengue infection but participants
had undetectable NS1 antigen levels (NS1 Ag) as in our
study. NS1 protein assay may be detected in serum sam-
ples during viremic period (~five days after the onset of
symptoms). Several studies detected relatively low sensi-
tivity of this test, below 50% when samples were
collected after seven days of symptoms [39-41]. Another
potential reason for the diverse results of viremia by RT-
PCR compared to the detection of NS1Ag could be the
low sensitivity of NS1 observed among population of
Nicaragua and Phillipines. These results were associated
with the distinct circulating serotype, duration of illness
previous to data collection and the presence of NS1-IgG
immune complex among secondary infected individuals
with consequently protein clearance [41].
Considering the oncoming dengue vaccine trials, the
transfer of dengue maternal antibodies to infants should
be taken into account due to the potential reduction of
vaccine efficacy and the ideal age of vaccination.
Additionally, maternal dengue antibodies are considered
to enhance the disease severity among infants [14,15].
Because this study design was cross-sectional, pre- and
post-natal follow-up to measure the incidence of dengue
infection and clinical dengue cases among women and the
kinetics of maternal dengue antibodies among infants
were beyond the scope of the current investigation.
One of the limitations of this study was that single or
multiple DENV infections by specific subtypes were not
identified in the subpopulation of pregnant women and
neonates. Detecting the serotypes of DENV by the
plaque reduction neutralization test (PRNT) is desirable.
However, this laboratory technique is laborious and re-
quires a skilled technical staff [42]. We are also aware of
the limited representativeness of the studied population,
which included the subpopulation of pregnant women
from selected recruitment settings in a city located in
central Brazil.
Finally, regional endemic scenarios should be taken
into account when modelling the disease burden in this
subpopulation and the effectiveness of interventions,
such as vaccination, in a large country such as Brazil.
Conclusion
In central Brazil, the current epidemiological pattern of
dengue infection showed that half of the pregnant
women had an immunological marker of past dengue
exposure with similar frequency of placental transfer of
maternal IgG antibodies, providing short-term protection
for their neonates. This study provides critical data on the
prevalence of transplacental transferred maternal-infant
anti-dengue antibodies. The design of future vaccine trials
should consider the diverse regional epidemiological
scenarios regarding naive and immune population.
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